Colorectal Cancer Screening. Health Impact and Cost Effectiveness

American Journal of Preventive Medicine

Volumn 31, Issue 1, 2006, Pages 80-89

  Maciosek, Michael V ^a   Solberg, Leif I ^a   Coffield, Ashley B ^b   Edwards, Nichol M ^a   Goodman, Michael J ^a  

^a HEALTHPARTNERS RESEARCH FOUNDATION   (United States)

^b Partnership for Prevention   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SCREENING; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; PREVENTIVE HEALTH SERVICE;

COLONOSCOPY; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; HUMANS; MASS SCREENING; MIDDLE AGED; PREVENTIVE HEALTH SERVICES;

EID: 33745444030     PISSN: 07493797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amepre.2006.03.009     Document Type: Article

References (91)

1. American Cancer Society. Cancer facts and figures 2005 (2005), American Cancer Society, Atlanta GA
2. Screening for colorectal cancer. recommendation and rationale. Ann Intern Med 137 (2002) 129-131
3. Balluz L., Ahluwalia I.B., Murphy W., Mokdad A., Giles W., and Harris V.B. Surveillance for certain health behaviors among selected local areas-United States, Behavioral Risk Factor Surveillance System, 2002. MMWR Surveill Summ 53 (2004) 1-100
4. Centers for Disease Control and Prevention. National Health Interview Survey 2003, public use data set. Available at: www.cdc.gov/nchs/nhis.htm. Accessed August 10, 2005.
5. Brawarsky P., Brooks D.R., Mucci L.A., and Wood P.A. Effect of physician recommendation and patient adherence on rates of colorectal cancer testing. Cancer Detect Prev 28 (2004) 260-268
6. Janz N.K., Wren P.A., Schottenfeld D., and Guire K.E. Colorectal cancer screening attitudes and behavior. a population-based study. Prev Med 37 (2003) 627-634
7. Coffield A.B., Maciosek M.V., McGinnis J.M., et al. Priorities among recommended clinical preventive services. Am J Prev Med 21 (2001) 1-9
8. Maciosek M.V., Edwards N.M., Coffield A.B., et al. Priorities among effective clinical preventive services. methods. Am J Prev Med 31 (2006) 90-96
9. Winawer S., Fletcher R., Rex D., et al. Colorectal cancer screening and surveillance. clinical guidelines and rationale-update based on new evidence. Gastroenterology 124 (2003) 544-560
10. Bertario L., Russo A., Crosignani P., et al. Reducing colorectal cancer mortality by repeated faecal occult blood test. a nested case-control study. Eur J Cancer 35 (1999) 973-977
11. Ederer F., Church T.R., and Mandel J.S. Fecal occult blood screening in the Minnesota study. role of chance detection of lesions. J Natl Cancer Inst 89 (1997) 1423-1428
12. Faivre J., Tazi M.A., El Mrini T., Lejeune C., Benhamiche A.M., and Dassonville F. Faecal occult blood screening and reduction of colorectal cancer mortality. a case-control study. Br J Cancer 79 (1999) 680-683
13. Hardcastle J.D., Chamberlain J.O., Robinson M.H., et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 348 (1996) 1472-1477
14. Jorgensen O.D., Kronborg O., and Fenger C. A randomised study of screening for colorectal cancer using faecal occult blood testing. results after 13 years and seven biennial screening rounds. Gut 50 (2002) 29-32
15. Kronborg O., Fenger C., Olsen J., Bech K., and Sondergaard O. Repeated screening for colorectal cancer with fecal occult blood test. A prospective randomized study at Funen, Denmark. Scand J Gastroenterol 24 (1989) 599-606
16. Kronborg O., Fenger C., Olsen J., Jorgensen O.D., and Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 348 (1996) 1467-1471
17. Lamah M., Norris J., Caffarey S.M., Broughton M., and Marks C.G. Effect of faecal occult blood testing on colorectal cancer mortality in the surveillance of subjects at moderate risk of colorectal neoplasia. a case-control study. Int J Colorectal Dis 16 (2001) 313-317
18. Lazovich D., Weiss N.S., Stevens N.G., White E., McKnight B., and Wagner E.H. A case-control study to evaluate efficacy of screening for faecal occult blood. J Med Screen 2 (1995) 84-89
19. Mandel J.S., Bond J.H., Church T.R., et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 328 (1993) 1365-1371
20. Mandel J.S., Church T.R., Ederer F., and Bond J.H. Colorectal cancer mortality. effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 91 (1999) 434-437
21. Muller A.D., and Sonnenberg A. Protection by endoscopy against death from colorectal cancer. A case-control study among veterans. Arch Intern Med 155 (1995) 1741-1748
22. Newcomb P.A., Norfleet R.G., Storer B.E., Surawicz T.S., and Marcus P.M. Screening sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst 84 (1992) 1572-1575
23. Niv Y., Lev-El M., Fraser G., Abuksis G., and Tamir A. Protective effect of faecal occult blood test screening for colorectal cancer. worse prognosis for screening refusers. Gut 50 (2002) 33-37
24. Saito H., Soma Y., Koeda J., et al. Reduction in risk of mortality from colorectal cancer by fecal occult blood screening with immunochemical hemagglutination test. A case-control study. Int J Cancer 61 (1995) 465-469
25. Scheitel S.M., Ahlquist D.A., Wollan P.C., Hagen P.T., and Silverstein M.D. Colorectal cancer screening. a community case-control study of proctosigmoidoscopy, barium enema radiography, and fecal occult blood test efficacy. Mayo Clin Proc 74 (1999) 1207-1213
26. Scholefield J.H., Moss S., Sufi F., Mangham C.M., and Hardcastle J.D. Effect of faecal occult blood screening on mortality from colorectal cancer. results from a randomised controlled trial. Gut 50 (2002) 840-844
27. Selby J.V., Friedman G.D., Quesenberry Jr. C.P., and Weiss N.S. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 326 (1992) 653-657
28. Selby J.V., Friedman G.D., Quesenberry Jr. C.P., and Weiss N.S. Effect of fecal occult blood testing on mortality from colorectal cancer. A case-control study. Ann Intern Med 118 (1993) 1-6
29. Wahrendorf J., Robra B.P., Wiebelt H., Oberhausen R., Weiland M., and Dhom G. Effectiveness of colorectal cancer screening. results from a population-based case-control evaluation in Saarland, Germany. Eur J Cancer Prev 2 (1993) 221-227
30. Winawer S.J., Flehinger B.J., Schottenfeld D., and Miller D.G. Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy. J Natl Cancer Inst 85 (1993) 1311-1318
31. Zappa M., Castiglione G., Grazzini G., et al. Effect of faecal occult blood testing on colorectal mortality. results of a population-based case-control study in the district of Florence, Italy. Int J Cancer 73 (1997) 208-210
32. Mapp T.J., Hardcastle J.D., Moss S.M., and Robinson M.H. Survival of patients with colorectal cancer diagnosed in a randomized controlled trial of faecal occult blood screening. Br J Surg 86 (1999) 1286-1291
33. Khandker R.K., Dulski J.D., Kilpatrick J.B., Ellis R.P., Mitchell J.B., and Baine W.B. A decision model and cost-effectiveness analysis of colorectal cancer screening and surveillance guidelines for average-risk adults. Int J Technol Assess Health Care 16 (2000) 799-810
34. Vijan S., Hwang E.W., Hofer T.P., and Hayward R.A. Which colon cancer screening test? A comparison of costs, effectiveness, and compliance. Am J Med 111 (2001) 593-601
35. Song K., Fendrick A.M., and Ladabaum U. Fecal DNA testing compared with conventional colorectal cancer screening methods. a decision analysis. Gastroenterology 126 (2004) 1270-1279
36. Maciosek M.V., Coffield A.B., McGinnis J.M., et al. Methods for priority setting among clinical preventive services. Am J Prev Med 21 (2001) 10-19
37. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: mortality-all COD, public-use with state, total U.S. (1969-2000), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2003. Available at: www.seer.cancer.gov. Accessed January 25, 2005.
38. Arias E. United States life tables, 2000. Natl Vital Stat Rep 51 (2002) 1-38
39. Nadel M.R., Blackman D.K., Shapiro J.A., and Seeff L.C. Are people being screened for colorectal cancer as recommended? Results from the National Health Interview Survey. Prev Med 35 (2002) 199-206
40. Subramanian S., Amonkar M.M., and Hunt T.L. Use of colonoscopy for colorectal cancer screening. evidence from the 2000 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev 14 (2005) 409-416
41. Muller A.D., and Sonnenberg A. Prevention of colorectal cancer by flexible endoscopy and polypectomy. A case-control study of 32,702 veterans. Ann Intern Med 123 (1995) 904-910
42. Slattery M.L., Edwards S.L., Ma K.N., and Friedman G.D. Colon cancer screening, lifestyle, and risk of colon cancer. Cancer Causes Control 11 (2000) 555-563
43. Newcomb P.A., Storer B.E., Morimoto L.M., Templeton A., and Potter J.D. Long-term efficacy of sigmoidoscopy in the reduction of colorectal cancer incidence. J Natl Cancer Inst 95 (2003) 622-625
44. Rasmussen M., Kronborg O., Fenger C., and Jorgensen O.D. Possible advantages and drawbacks of adding flexible sigmoidoscopy to hemoccult-II in screening for colorectal cancer. A randomized study. Scand J Gastroenterol 34 (1999) 73-78
45. Kewenter J., Brevinge H., Engaras B., Haglind E., and Ahren C. Results of screening, rescreening, and follow-up in a prospective randomized study for detection of colorectal cancer by fecal occult blood testing. Results for 68,308 subjects. Scand J Gastroenterol 29 (1994) 468-473
46. Myers R.E., Balshem A.M., Wolf T.A., Ross E.A., and Millner L. Adherence to continuous screening for colorectal neoplasia. Med Care 31 (1993) 508-519
47. Hardcastle J.D., Balfour T.W., and Amar S.S. Screening for symptomless colorectal cancer by testing for occult blood in general practice. Lancet 1 (1980) 791-793
48. Thrasher J.F., Cummings K.M., Michalek A.M., Mahoney M.C., Moysich K.B., and Pillittere D.M. Colorectal cancer screening among individuals with and without a family history. J Public Health Manag Pract 8 (2002) 1-9
49. Ore L., Hagoel L., Lavi I., and Rennert G. Screening with faecal occult blood test (FOBT) for colorectal cancer. assessment of two methods that attempt to improve compliance. Eur J Cancer Prev 10 (2001) 251-256
50. Hart A.R., Eaden J., Barnett S., de Bono A.M., and Mayberry J.F. Colorectal cancer prevention. An approach to increasing compliance in a faecal occult blood test screening programme. J Epidemiol Community Health 52 (1998) 818-820
51. Grazzini G., Castiglione G., Isu A., et al. Colorectal cancer screening by fecal occult blood testing. results of a population-based experience. Tumori 86 (2000) 384-388
52. Brevinge H., Lindholm E., Buntzen S., and Kewenter J. Screening for colorectal neoplasia with faecal occult blood testing compared with flexible sigmoidoscopy directly in a 55-56 years' old population. Int J Colorectal Dis 12 (1997) 291-295
53. Hart A.R., Barone T.L., Gay S.P., et al. The effect on compliance of a health education leaflet in colorectal cancer screening in general practice in central England. J Epidemiol Community Health 51 (1997) 187-191
54. Church T.R., Yeazel M.W., Jones R.M., et al. A randomized trial of direct mailing of fecal occult blood tests to increase colorectal cancer screening. J Natl Cancer Inst 96 (2004) 770-780
55. Verne J.E., Aubrey R., Love S.B., Talbot I.C., and Northover J.M. Population based randomized study of uptake and yield of screening by flexible sigmoidoscopy compared with screening by faecal occult blood testing. BMJ 317 (1998) 182-185
56. Zack D.L., DiBaise J.K., Quigley E.M., and Roy H.K. Colorectal cancer screening compliance by medicine residents. perceived and actual. Am J Gastroenterol 96 (2001) 3004-3008
57. Thiis-Evensen E., Hoff G.S., Sauar J., Langmark F., Majak B.M., and Vatn M.H. Population-based surveillance by colonoscopy: effect on the incidence of colorectal cancer. Telemark Polyp Study I. Scand J Gastroenterol 34 (1999) 414-420
58. Thiis-Evensen E., Hoff G.S., Sauar J., Majak B.M., and Vatn M.H. Flexible sigmoidoscopy or colonoscopy as a screening modality for colorectal adenomas in older age groups? Findings in a cohort of the normal population aged 63-72 years. Gut 45 (1999) 834-839
59. Thiis-Evensen E., Hoff G.S., Sauar J., Majak B.M., and Vatn M.H. The effect of attending a flexible sigmoidoscopic screening program on the prevalence of colorectal adenomas at 13-year follow-up. Am J Gastroenterol 96 (2001) 1901-1907
60. Segnan N., Senore C., Andreoni B., et al. Baseline findings of the Italian multicenter randomized controlled trial of "once-only sigmoidoscopy"-SCORE. J Natl Cancer Inst 94 (2002) 1763-1772
61. Bretthauer M., Gondal G., Larsen K., et al. Design, organization and management of a controlled population screening study for detection of colorectal neoplasia. attendance rates in the NORCCAP study (Norwegian Colorectal Cancer Prevention). Scand J Gastroenterol 37 (2002) 568-573
62. Weissfeld J.L., Ling B.S., Schoen R.E., Bresalier R.S., Riley T., and Prorok P.C. Adherence to repeat screening flexible sigmoidoscopy in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer 94 (2002) 2569-2576
63. McCarthy B.D., and Moskowitz M.A. Screening flexible sigmoidoscopy. patient attitudes and compliance. J Gen Intern Med 8 (1993) 120-125
64. Hoff G., Sauar J., Vatn M.H., et al. Polypectomy of adenomas in the prevention of colorectal cancer: 10-year follow-up of the Telemark Polyp Study I. A prospective, controlled population study. Scand J Gastroenterol 31 (1996) 1006-1010
65. Blom J., Liden A., Jeppsson B., Holmberg L., and Pahlman L. Compliance and findings in a Swedish population screened for colorectal cancer with sigmoidoscopy. Eur J Surg Oncol 28 (2002) 827-831
66. Elwood J.M., Ali G., Schlup M.M., et al. Flexible sigmoidoscopy or colonoscopy for colorectal screening. a randomized trial of performance and acceptability. Cancer Detect Prev 19 (1995) 337-347
67. Turner B.J., Weiner M., Yang C., and TenHave T. Predicting adherence to colonoscopy or flexible sigmoidoscopy on the basis of physician appointment-keeping behavior. Ann Intern Med 140 (2004) 528-532
68. Denberg T.D., Melhado T.V., Coombes J.M., et al. Predictors of nonadherence to screening colonoscopy. J Gen Intern Med 20 (2005) 989-995
69. Corbett M., Chambers S.L., Shadbolt B., Hillman L.C., and Taupin D. Colonoscopy screening for colorectal cancer. the outcomes of two recruitment methods. Med J Aust 181 (2004) 423-427
70. Wagner J.L., Tunis S., Brown M., Ching A., and Almeida R. Cost-effectiveness of colorectal cancer screening in average-risk adults (1996) 321-341
71. Sirovich B.E., Schwartz L.M., and Woloshin S. Screening men for prostate and colorectal cancer in the United States. does practice reflect the evidence?. JAMA 289 (2003) 1414-1420
72. Gold M.R. Cost-effectiveness in health and medicine (1996), Oxford University Press, New York
73. Frazier A.L., Colditz G.A., Fuchs C.S., and Kuntz K.M. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA 284 (2000) 1954-1961
74. Sonnenberg A., Delco F., and Inadomi J.M. Cost-effectiveness of colonoscopy in screening for colorectal cancer. Ann Intern Med 133 (2000) 573-584
75. Theuer C.P., Wagner J.L., Taylor T.H., et al. Racial and ethnic colorectal cancer patterns affect the cost-effectiveness of colorectal cancer screening in the United States. Gastroenterology 120 (2001) 848-856
76. U.S. Department of Labor, Bureau of Labor Statistics. Employer costs for employee compensation historical listing (annual), 1986-2001 (2002), Bureau of Labor Statistics, Washington DC June 19
77. Pignone M., Saha S., Hoerger T., Mandelblatt J., and Preventive Services Task Force. Cost-effectiveness analyses of colorectal cancer screening. a systematic review for the U.S. Ann Intern Med 137 (2002) 96-104
78. In: Pignone M., Russell L., and Wagner J. (Eds). Economic models of colorectal cancer screening in average risk adults. workshop summary (2005), National Academies Press, Washington DC
79. Shapiro J.A., Seeff L.C., and Nadel M.R. Colorectal cancer-screening tests and associated health behaviors. Am J Prev Med 21 (2001) 132-137
80. Lewis S.F., and Jensen N.M. Screening sigmoidoscopy. Factors associated with utilization. J Gen Intern Med 11 (1996) 542-544
81. Zapka J.G., Puleo E., Vickers-Lahti M., and Luckmann R. Healthcare system factors and colorectal cancer screening. Am J Prev Med 23 (2002) 28-35
82. Ioannou G.N., Chapko M.K., and Dominitz J.A. Predictors of colorectal cancer screening participation in the United States. Am J Gastroenterol 98 (2003) 2082-2091
83. Chao A., Connell C.J., Cokkinides V., Jacobs E.J., Calle E.E., and Thun M.J. Underuse of screening sigmoidoscopy and colonoscopy in a large cohort of U.S. adults. Am J Public Health 94 (2004) 1775-1781
84. Seeff L.C., Nadel M.R., Klabunde C.N., et al. Patterns and predictors of colorectal cancer test use in the adult U.S. population. Cancer 100 (2004) 2093-2103
85. Sutton S., Wardle J., Taylor T., et al. Predictors of attendance in the United Kingdom flexible sigmoidoscopy screening trial. J Med Screen 7 (2000) 99-104
86. Lemon S., Zapka J., Puleo E., Luckmann R., and Chasan-Taber L. Colorectal cancer screening participation. comparisons with mammography and prostate-specific antigen screening. Am J Public Health 91 (2001) 1264-1272
87. Cokkinides V.E., Chao A., Smith R.A., Vernon S.W., and Thun M.J. Correlates of underutilization of colorectal cancer screening among U.S. adults, age 50 years and older. Prev Med 36 (2003) 85-91
88. Straus W.L., Mansley E.C., Gold K.F., Wang Q., Reddy P., and Pashos C.L. Colorectal cancer screening attitudes and practices in the general population. a risk-adjusted survey. J Public Health Manag Pract 11 (2005) 244-251
89. Maciosek M.V., Coffield A.B., Edwards N.M., Flottemesch T.J., Goodman M.J., and Solberg L.I. Priorities among effective clinical preventive services. results of a systematic review and analysis. Am J Prev Med 31 (2006) 52-61
90. Solberg L.I., Maciosek M.V., Edwards N.M., Khandchandani H.S., and Goodman M.J. Repeated tobacco-use screening and intervention in clinical practice. health impact and cost effectiveness. Am J Prev Med 31 (2006) 62-71
91. Maciosek M.V., Solberg L.I., Coffield A.B., Edwards N.M., and Goodman M.J. Influenza vaccination. health impact and cost effectiveness among adults aged 50 to 64 and 65 and older. Am J Prev Med 31 (2006) 72-79